Previous 10 | Next 10 |
Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences PR Newswire NEW YORK , April 25, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral...
Immunic (NASDAQ:IMUX) announced that Glenn Whaley, CPA, who has served as VP Finance, Principal Financial and Accounting Officer since April 2020, has been promoted to CFO position. He has 30+ years of experience in accounting and finance and is with the company since 2019. "Wi...
Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer PR Newswire NEW YORK , March 16, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ora...
Immunic (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus ...
Immunic, Inc. to Participate in Investor and Scientific Conferences in March PR Newswire NEW YORK , March 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology thera...
Immunic inc. (IMUX) Q4 2021 Earnings Conference Call February 24, 2021, 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – VP of Finance and Principal Financial & Accounting Officer Andreas Muehler – Chief Me...
The following slide deck was published by Immunic, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Immunic, Inc. 2021 Q4 - Results - Earnings Call Presentation
Immunic press release (NASDAQ:IMUX): FY GAAP EPS of -$3.93 misses by $0.04. Cash and Cash Equivalents as of December 31, 2021 were $86.9M For further details see: Immunic GAAP EPS of -$3.93 misses by $0.04
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity - Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 D...
Immunic (NASDAQ:IMUX) is scheduled to announce FY earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$3.73 For further details see: Immunic FY 2021 Earnings Preview
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...